Treatment After Palbociclib-containing Regimens

A Multi-center Study of the Treatment Patterns and Clinical Outcomes of Subsequent Therapies After Progression on Palbociclib in HR+/HER2- Metastatic Breast Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04517318

Enrollment

200

Registered

2020-08-18

Start date

2017-08-15

Completion date

2021-07-15

Last updated

2021-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

To evaluate the prescription patterns and treatment outcomes of subsequent therapies after progression on palbociclib in the real world.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. woman, age \> 18 years old 2. Diagnosed with HR+/HER2- Metastatic Breast Cancer 3. Patients received at least one-cycle next-line treatment after progression on combined palbociclib and endocrine therapy 4. Complete medical history was available

Exclusion criteria

1\. Medical history was incomplete

Design outcomes

Primary

Measure	Time frame	Description
PFS	6 weeks	Progression free survival
Adverse events	6 weeks	Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)

Countries

China

Outcome results